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Introduction 
 
This preliminary report presents the early observations and analysis from a multi-year 
study of the life science ecosystem centred on the University of Edinburgh College of 
Medicine and Veterinary Medicine. It incorporates market study work conducted by 
the Edinburgh BioQuarter and ongoing research at the Centre for Entrepreneurship 
Research at the University of Edinburgh Business School. 
Connections between the fields of medicine and business management are, 
historically speaking, a relatively new phenomena. The rise of the pharmaceutical 
industry on a global basis, the promise of biotechnology, government funded 
foundational research and the expansion and consolidation of the health services and 
insurance industry in the United States have led to unprecedented investments in life 
sciences. Although the predominance of revenue and profits in these fields is 
generated by large, increasingly transnational organizations, government and 
educational institutions have found inspiration in the entrepreneurial stories of 
innovative, high growth life science ventures. To be sure, the job creation and tax 
income value of these organizations is only realized after they grow out of the 
entrepreneurial stage, but universities and policymakers have often found better levers 
of influence in the creation and support of de novo firms. 
The complexity of foundational research, product development and regulatory 
frameworks generally requires most life science companies to subsist on external 
finance, such as venture capital, for many years prior to market entry. In contrast to 
high-growth firms in the software and internet sectors which may experience 
explosive growth within a few years of launch, the cultivation of life science 
companies requires long runways and investor patience. In theory, this would appear 
well-aligned with the strategic vision of research universities. The institutionally-
driven evolution of technology transfer capabilities at universities sometimes results 
in monolithic treatment of life science innovations, based on relatively short-term 
expectations for recouping patent filing and administration costs. 
In this context, we initiated a multi-year study of the ongoing development of the life 
science ecosystem in and around the College of Medicine and Veterinary Medicine 
(CMVM) at the University of Edinburgh. CMVM is, in both research and practice, 
one of the top medical institutions in Europe. To complement its research and clinical 
capabilities, a significant investment by the University and the Scottish government 
has created the Edinburgh BioQuarter to support university-industry engagement and 
innovation commercialization. This appears to present some of the key resources and 
capabilities associated with the very early stages of a life sciences economic cluster. 
The study has both research and practice-driven goals: 
1) Chronicle the development of the ecosystem during formative stages, 
2) Address relevant research questions about entrepreneurial behaviour within a 
large-scale institutional context 
3) Test some of the extant organizational and entrepreneurial theories about 
innovation management and venture formation at the university-industry 
boundary 
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4) Provide advice to researchers, administrators, entrepreneurs, and policymakers 
on how to facilitate successful commercialization activities that benefit all 
stakeholders: universities, entrepreneurs, industry, and society. 
This report presents some of our preliminary findings. Although we believe our 
observations and preliminary conclusions are well-founded, they are subject to 
revision as the study continues. The study is scheduled to conclude in late 2013. A 
final report will be published in late 2013 or early 2014 to present summary findings. 
The Context: the UK biotechnology industry today 
As of 2012, the outlook for biotechnology in the UK and Europe may appear less than 
secure. Overall employment in UK biotech has remained static for nearly ten years.
1
 
Some regions have experienced declines in biotechnology-related employment, 
usually due to the loss of a single significant organization. One example was the 
departure of Merck from central Scotland in 2009 with the loss of more than 250 jobs. 
The global financial crisis has had severe short-term effects on the global 
biotechnology capital market.  Private investment in new biotechnology ventures fell 
from US$2.75 billion to US$ 2 billion between 2009 and 2010,
2
 and only half as 
many new firms were funded in 2011 as in 2010. As is common during economic 
downturns, venture capitalists focus on managing investment portfolios rather than 
risking significant capital on new ventures. The repercussions of near-term resource 
constraints for early stage biotechnology ventures will be likely last many years. In 
the near-term, there will be fewer high-growth potential life science companies. In the 
long-term, there may be fewer large-scale exit events that generate high investment 
returns for the VCs and fewer “portfolio” entrepreneurs who start and fund related, 
follow-on ventures.
3
 
Notwithstanding these challenges, life science research remains vibrant worldwide, 
and the social and economic impact of medical technology has never been more 
apparent. Successful innovation generates significant rewards at every stage of the 
technology development cycle. The global consolidation of the pharmaceutical 
industry means greater rewards for drug discovery and biotechnology firms that feed 
the drug development pipeline or provide the tools to make the pipeline more 
efficient. Entirely new business models for the provision of health care in developing 
nations target large, previously inaccessible markets. In addition, the continued 
development of life science research generates opportunities for related businesses 
that build on complementary capabilities. FIOS Genomics, for instance, is technically 
a data analysis company, but it combines 50 years of research and management 
expertise from the University of Edinburgh spanning genomics, pathway medicine 
and computer science to deliver bio-statistical datasets to its customers.  
Broad economic trends aside, there are indications of support for the industry from the 
UK government. In the 2011/12 budget, Chancellor George Osbourne announced an 
increase in R&D tax credits from 100% to 225% for science-based firms; a decrease 
in corporation tax from 28% to 23%; and an increase in the tax-free allowance to 
                                                 
1
 Source: DTZ Ltd, 2011 (private research for UK biotechnology companies) 
2
 Source: BioWorld Today, Tuesday March 29, 2011, “Biotechnology seeks alternative funding 
models” 
3
 Source: Rosa, P (1998). Entrepreneurial Processes of Business Cluster Formation and Growth by 
'Habitual' Entrepreneurs. Entrepreneurship Theory and Practice, 22 (4): 43-62. 
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angel investors in scientific companies from £2 million to £10 million.
4
 Such 
measures are likely to increase access to resources for the development of the UK 
biotechnology industry.  
Facilitating the development of sustainable life science clusters, or ecosystems,  
remains an important challenge for realising both the social and economic benefits of 
biotechnology. The “triple helix” model linking university-academic-industry 
collaboration to the development of local and regional knowledge economies presents 
an attractive and intuitive mechanism for explaining the development of such 
clusters.
5
 Realistically, however, the anecdotal success of a handful of high-profile 
clusters, such as San Diego, Boston, and Medicon Valley (Europe), must be 
understood as exceptions rather than exemplars. Professor Anne Miner, an 
internationally-recognized management and entrepreneurship scholar, describes these 
cases where university technology transfer has directly and significantly impacted 
regional economic development as “magic beanstalks.” She cautions that examples of 
limited success and near-term failure are far more prevalent.
6
 Growing the beanstalk 
requires more than simply scattering seeds of new ventures randomly into the market. 
At the core of success is a cost-effective and efficient model for translating findings 
from research conducted at life science research facilities into viable products and 
services. 
Success, then, requires talent, determination, and some good fortune. There are many 
lessons to be learned from successful programmes; implementing best practices 
increases the likelihood that good fortune may be capitalized. The resources and 
processes that support the beanstalk, even without the “magic,” provide a foundation 
for the creation of high value-add organisations and the development of important 
new technologies and treatments. These elements form a constellation of assets that 
benefit patients, the healthcare industry and the economy. 
The unreliable magic of university-based technology transfer 
The scientific and economic impacts of university-based technology transfer are 
significant. As examples, Northwestern University received $700 million for the 
rights to the therapeutic Lyrica,
7
 and Stanford earned $336 million from the sale of 
Google stock obtained in the spin-out licensing process.
8
 In 2010, more than 5000 
licenses were executed, 500 new start-ups were formed, and nearly $3B in total 
revenue generated by American university technology transfer offices.
9
 It is not 
surprising, then, that innovators, university administrators, and policy-makers often 
look to research-based academic institutions as both hubs of innovation and potential 
drivers of regional economic development. As most research universities derive 
                                                 
4
 Source: The Evening Standard, 24 March 2011, “Chancellor announces good news for biotech firms” 
5
 Source: Universities and the Global Knowledge Economy, edited by Etzkowitz, H and Leydesdorff, 
editors. 2002. Continuum International: New York. 
6
 Miner, AS. et al (2000).  “The magic beanstalk vision of university venture formation.” In The 
Entrepreneurship Dynamic.  (Eds. Kaye Schoonhoven and Elaine Romanelli).  Stanford, CA: 
Stanford University Press. 
7
 Mantone, J. (2007). “Pfizer’s Lyrica Gives Another Boost to Northwestern.” Wall Street Journal 
Health Blog, December 19. 
8
 Krieger, L. (2005). “Stanford Earns $336 Million Off Google Stock.” San Jose Mercury News, 
December 1. 
9
 The Association of University Technology Managers (2010). “University Technology Transfer: Why 
We Do What We Do.” www.autm.net accessed 1-May 2011. 
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funding from public sources, there is often an added perception that technology 
transfer offices (TTOs) at those institutions have a responsibility to generate 
economic outcomes to justify public investment. A few institutions seem to have 
fulfilled this potential, and are commonly interpreted as examples for the rest. 
But in the world of university technology transfer, licenses and spinouts that generate 
millions of dollars in stock and royalty revenues for TTOs are outliers.
10
 It is 
important to place cases like Google, Remicade, and Tomotherapy in context. The $2-
3 billion of licensing income generated by American universities stems from roughly 
$55 billion of total sponsored research. And while many university technologies 
represent high potential innovations, most emerge from university laboratories 
unproven in any commercial context. The technologies licensed through university 
technology transfer, almost without exception, will require many years and millions 
of pounds to become commercially-viable products. In fact, the majority will never 
see the market at all. 
Leadership in practice: Imperial College London 
Ranked the 9
th
 best University in the world in 2011, Imperial College London 
employs 68 fellows of the Royal Society, with 14 Nobel Prize winners and two Fields 
Medallists among former faculty. Through its equity investment arm, Imperial 
Innovations Limited, Imperial holds stakes in eighty companies with a total value of 
these stakes of more than £90 million 
Since 2005, Imperial College London has created eight new life sciences companies 
with a total investment value of £18 million pounds at launch. One of these 
companies, Respivert, was sold to Centocor Biotech for £9.5million, netting Imperial 
a return of 470% over a three-year investment. In 2010, Imperial Innovations Ltd 
declared pre-tax profits of £5.5million, up 5% over 2009. 
Geographical concentration: London is home to many of the nation’s most highly 
regarded medical schools and research institutes, including Guy’s Hospital, 
Moorfields Eye Hospital, University College London and the new UK Centre for 
Medical Research at Kings Cross. 
 Access to venture capital: London is one of the world’s greatest financial capitals, 
with more assets under management than any other location apart from New York. 
Imperial Innovations itself is AIM-listed and has more than £90m invested in 66 
companies. 
Infrastructure and process: Imperial Innovations handles more than 350 innovation 
disclosures a year. A new ventures team handles these disclosures, turning them into 
embryonic companies if appropriate. New companies are then handed over to an 
investment team for further development before being launched, including the 
creation of senior management teams and acquisition of venture capital investment. 
Imperial Innovations also runs business plan competitions and manages an 
“Entrepreneurs in Residence” programme.  
                                                 
10
 Bock, AJ. 2012. “Technology Transfer” in (ed. Marvel) Encyclopedia of New Venture Management. 
SAGE Publications: Thousand Oaks, CA. 
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The mundane behind the magic 
The promise of university-based technology transfer for generating sustained 
economic development has been labelled a “Magic Beanstalk” by eminent 
management researcher Anne Miner.
11
 In a detailed study of technology transfer at 
universities in eight countries, Miner and her colleagues showed that traditional views 
about the university’s role in knowledge exchange have changed to include direct 
economic value creation. Whereas extensive research demonstrates the economic 
impact of training students and knowledge dissemination via various communication 
and media, many universities have focused efforts on licensing technologies to extant 
businesses and de novo ventures. These represent more direct mechanisms linking 
commercial economic activity to university research, with the added potential benefit 
of generating financial returns for the institution. 
But three myths underlie the “magic beanstalk” vision. The first myth is that any 
university can launch successful spin-outs and start-ups. The second myth is that job 
creation inevitably follows from university-inspired venturing. The third myth is that 
this type of venturing helps address local job creation problems.  
In reality, the economic promise of technology transfer, is limited by a numerous 
factors. The majority of de novo venturing occurs in very specific fields: computer 
science, life science, and a narrow range of natural sciences. These types of firms 
have high failure rates, despite the benefits of university origin. And because these 
firms tend to emerge and develop in geographical clusters, the positive economic 
impacts of firm formation may not accrue to the local area of origin. 
The reality of university-based technology transfer is not a fairy tale with an 
inevitably happy ending. First, with the exception of universities benefiting from one-
off licenses for blockbuster therapeutics, the most successful technology transfer 
universities are generally those that have consistently invested extensive financial 
resources over lengthy periods of time. Institutions like Stanford, MIT, and the 
University of Wisconsin facilitate successful licensing and venturing practice with a 
small army of technology, legal, and development experts based on decades of history 
and experience. And while Imperial College London may seem like a newcomer to 
world-class status, Imperial Innovations has been commercializing technology for 25 
years. Imperial, in particular, has benefited from the combination of significant 
financial investment, a culture that emphasizes the social and commercial impact of 
research, and an extraordinary network linking researchers to industry. 
Beyond the magic beanstalk: an entrepreneurial perspective 
University technology transfer benefits from both hard work as well as long-term 
investment in systems, infrastructure, and knowledgeable individuals. In addition, the 
development of so-called “clusters” or “eco-systems” depends on many factors.12 
                                                 
11
 Miner, AS. et al (2000).  “The magic beanstalk vision of university venture formation.” In The 
Entrepreneurship Dynamic.  (Eds. Kaye Schoonhoven and Elaine Romanelli).  Stanford, CA: 
Stanford University Press. 
12
 Menzel, M. P., & Fornahl, D. (2010). Cluster life cycles-dimensions and rationales 
of cluster evolution. Industrial and Corporate Change, 19(1), 205-238. 
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Leadership in practice: Cambridge University 
The process of translation between university research and commercial firms doesn’t 
happen overnight: despite the best will of universities, governments and investors, 
partnerships take time to mature. Cambridge University, perhaps Europe’s most 
successful example of a bio-technology cluster, has had institutional support for bio-
technology company creation since 1995. Since 2005, Cambridge has spun out eight 
life sciences companies with total first-round funding in excess of £12 million. All 
these companies are still trading, and many have secured licensing deals or additional 
rounds of funding. 
Geographical Concentration: In addition to the university itself, Cambridge co-
locates the Medical Research Council, Addenbrookes’ Hospital with XXX beds, and 
the British Biological Sciences Research Council at Babraham. There are also two 
science and technology parks in the greater Cambridge area. 
Access to Venture Capital: Abingworth, one of the world’s leading Life Sciences 
Venture Capital firms, opened its Cambridge office in 1989. Other venture capital 
firms active in Cambridge include Advent, Amadeus, New Hill and Chord Capital. 
These companies are joined by three university funds that provide a total of £7.3 
million of seed funding for early-stage ventures. 
Support: Cambridge runs two student Entrepreneur clubs that run business plan 
competitions for students and postgraduates. Additionally, there are investment 
forums at Babraham and the “Access” consortium to allow early-stage biotech 
ventures access to up to £7 million of early stage capital. The biotechnology industry 
is also supported by strong local government network, including the Cambridge 
Technopole and the East of England Development Agency. 
Critical Mass: with seven science parks, two hospitals, the world’s leading university 
and eight active life science venture capital investors, Cambridge has the critical mass 
essential to successful biotechnology transfer between universities and industry. 
Promoting the Entrepreneurial Spirit: A “Cambridge Phenomenon conference”, 
held in Q4 2010, suggests that those working in Cambridge recognise that, despite its 
obvious advantages, the region still needs to improve to achieve world-class status as 
a bio-cluster, as one speaker puts it, “We may have many of the features of a Silicon 
Valley-type innovation ecosystem, but we are still not completely, “getting it.” Centre 
for Entrepreneurship represents a significant commitment by the University to 
facilitating both entrepreneurial activity within the University as well as interactions 
with industry. 
While the impact of a major research institution should not be underestimated, 
rigorous research has repeatedly demonstrated that organizational heterogeneity and 
broadly-based absorptive capacity in the form of extensive and dense networks of 
technologists, industrialists, financiers, and entrepreneurs are essential to cluster 
formation.
13
 
                                                 
13
 Zucker, L. G., Darby, M. R., & Armstrong, J. (1998). Geographically localized knowledge: 
Spillovers or markets? Economic Inquiry, 36(1), 65-86. 
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The clustering model and magic beanstalk rebuttal both approach the incubation and 
fostering of a life science cluster as a fundamentally institutional process. In this 
context, the critical drivers and leverage points are the policies and norms of the 
institutions played out against exogenous market forces and economic factors. To be 
sure, all entrepreneurial activity functions within these parameters, and some 
conditions are more conducive to encouraging economically desirable outcomes such 
as growth in skilled employment. But entrepreneurship is fundamentally an 
individual- and team-based endeavour. To ignore the role of the entrepreneur in the 
development of a life science cluster, especially at the university-industry boundary, 
fails to account for the idiosyncratic and creative potential of the people who will 
create and grow the cluster. 
Extensive research has shown that financial incentives are not the sole or even 
primary driver of entrepreneurial activity at the university-industry interface.
14
 In 
addition, the research on “inventing entrepreneurs,” academics who participate in the 
commercialization of their own research, demonstrates the learning value associated 
with both successful and unsuccessful venturing. In other words, the measurement of 
near-term success or failure at the individual and institutional levels may not be the 
best indications of cluster formation potential or progress. 
Although rigorous analysis on the financial returns to university-based venturing is 
still contested, other aspects of the impact of university venturing and industry 
engagement are emerging. Academic scientists who participation in ommercialization 
demonstrate an increase in high-quality research output, especially in the life 
sciences,
15
 where the scale of resources required to progress fundamental research 
commonly requires multi-institutional collaboration. Second, life science firms 
struggle to expand into market areas too far afield from core skills.
16
 This means that 
a constant influx of entirely new ventures is likely necessary in any given cluster to 
maximise the cluster’s innovative capacity. Finally, the roles of uncertainty, 
experimentation and luck cannot be entirely eliminated from a given industrial cluster. 
New ventures must experiment with product, service, and business model innovations 
precisely because the success of such innovations cannot be ascertained ex ante.
17
 In 
other words, it may be extremely difficult for policymakers and institutional 
administrators to align incentives with a tolerance for failure that facilitates high-
potential venturing activity. 
                                                 
14
 George G and Bock AJ (2008). Inventing Entrepreneurs. Prentice-Hall Pearson: Saddleback, New 
Jersey. 
15
 Research on academic scientist output. 
16
 George paper on intuition 
17
 Heirmann and Clarysse 2005. 
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Leadership in Practice: Oxford University 
The oldest university in the English-speaking world, Oxford has spun out some 15 life 
science companies in the period 2005-2009, with around £60 million of private capital 
raised. Oxford’s chemistry department alone is the largest in the developed world and 
can claim ten Nobel Prize winning chemists over the last eighty years.  
ASSETS: 
Geographical Concentration: Oxford is home to the John Radcliffe, a large tertiary 
teaching hospital, in addition to the university’s biochemistry, biology, information 
technology and engineering faculties. Other research assets located in Oxford include 
the Institute of Molecular Medicine and the William Dunn Pathology Institute. 
Access to Venture Capital: Oxford Technology has operated Venture Capital Trusts 
(VCTs) and Enterprise Capital Funds (ECFs) in the Oxford area since 1983, investing 
between £100,000 and £300,000 in early-stage private biotechnology companies. The 
IP Group, which began in Oxford, has supported many of the early-stage investments 
made in spin-out companies from Oxford University.  
Support: Oxford has created three investment funds to support technologies to 
commercialisation: the Oxford Invention Fund, ISIS University Innovation Fund and 
the Proof of Concept Fund, totalling some £6.8 million available to researchers for 
early-stage development of commercial applications. Additionally, ISIS Innovations 
Ltd, Oxford Unversity’s tech transfer unit, has set up the ISIS Angel Network, a not-
for-profit company designed to present new opportunities to private investors. 
 
An assessment framework for life science cluster development at the university-
industry boundary 
Cluster analysis based on traditional industrial organization economics derives from 
the seminal work of Harvard Professor Michael Porter. The role of the university in 
the initiation, cultivation, and development of a long time-horizon life science cluster 
requires a more flexible approach.  Our study combines Porter’s industry clustering 
theory with Professor Miner’s framework for the university’s idiosyncratic influence 
on cluster formation. As shown in the “practice leadership cases,” we specifically 
focus on the following six factors as the starting point of our research and analysis: 
1. Geographical concentration. The successful bio-technology cluster will have at 
least one academic research institute in close proximity to a clinical research 
institute, a teaching hospital and other vital resources, including imaging 
equipment and animal biology institutes 
 
2. Access to Venture Capital. There will be more than one significant venture 
capital firm with a local interest active in the area. Examples of this outside the 
UK include Mission Bay in San Francisco, Cambridge, Mass., and Medicon 
Valley in Denmark and Skäne, Sweden. 
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3. Support. Local firms with IT and physical sciences experience will be able to 
provide new bio-tech companies with the necessary legal, financial and 
intellectual property services to assist in the creation and development of the new 
venture. There will be experienced accountancy personnel available to hire on a 
consultancy or permanent basis.  
 
4. Critical Mass. There will be a critical mass of companies in the area which will 
deliver a talent pool of managers experienced in working in scientific companies, 
bench scientists at all levels of experience, a university providing graduates and 
post-graduate students seeking employment, and senior managerial talent in the 
local area who have experience of managing spin-outs.  
 
5. Quality of Life. Whilst this factor may appear to be “nice to have”, it has proven 
essential in persuading experienced and successful executives to relocate from 
elsewhere in the country and abroad. 
 
6. Entrepreneurial Culture and Capabilities. The influence of institutional, 
macro-economic, and industrial-economic factors can’t be ignored. At the same 
tie, a significant component of a cluster’s growth and resiliency is culture and 
capabilities framework in which nascent entrepreneurs operate. Ultimately, it is 
individuals and teams that drive commercialization activities, whether via 
licensing engagements or new venture formation. If the development of 
entrepreneurial capabilities is supported, and an evergreen community of 
commercially-savvy scientists emerges, new “inventing entrepreneurs” are more 
likely to initiate and maintain commercialization practice. 
 
A study of cluster incubation at The University of Edinburgh 
A history of research and clinical excellence combined with recent investments at the 
university-industry boundary present The University of Edinburgh’s College of 
Medicine and Veterinary Medicine as a nascent, high-potential life science ecosystem. 
This study has been undertaken to document the early development activities within 
the University as well as the current activities associated with technology 
commercialization and industry engagement.   
CMVM demonstrates world-class medical research and innovation capacity. The 
University of Edinburgh is rated first in the UK for clinical medical research and first 
in the UK for veterinary research.
18
 It is rated third worldwide for stem cell research 
based on publication impact.
19
 Scotland’s research in regenerative medicine was rated 
first in the world as recently as September 2010.
20
  
At the same time, university-based venturing in biotechnology in Scotland has been 
relatively limited. In the past five years, only one biotechnology firm has been spun-
out of the University of Edinburgh, and six others from other Scottish universities. 
                                                 
18
 Source: HM Government Research Assessment Exercise, 2008 
19
 UK Government, 2008 Research Assessment Exercise. See www.direct.gov.uk 
20
 Source: Province of Ontario for the Canadian Government, September 2010 
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The Edinburgh BioQuarter is designed to encourage enterprise at the university-
industry interface. In recent years, CMVM and the BioQuarter have invested in assets 
and capabilities to support engagement with industry. These notably include:  
 A commercialization support team with extensive experience in biotechnology 
venturing and collaboration,  
 New facilities including both commercial space targeted at extant life science 
firms as well as an incubator space for new ventures, and 
 A collaboration with NHS and industry for an annual innovation competition to 
encourage and reward health-based innovations developed at the University and 
NHS with the potential to mature into new ventures 
Summary and study progress 
Research and practice demonstrate that the emergence and development of industrial 
clusters derive from complex and highly idiosyncratic institutional and economic 
factors. Explaining cluster formation in hindsight often appears logical, but 
facilitating and predicting new cluster formation remains art rather than science. 
At the same time, the reality of cluster development processes likely falls somewhere 
between Porter’s overly optimistic framework and Miner’s cautionary analysis. To 
that end, there is much promise in the ongoing study to describe and assess the 
maturation of the nascent life sciences cluster centred on the University of 
Edinburgh’s College of Medicine and Veterinary Medicine. Over the next two years, 
extensive data collection, combined with review of historical documentation 
associated with the establishment of the Edinburgh BioQuarter, will reveal both 
micro- and macro-level mechanism that support or inhibit cluster development. While 
some findings will likely confirm prior research and case study examples, the 
circumstances and resources at Edinburgh present a unique opportunity to test 
theories of cluster facilitation and maturation in real-time. In addition, the study plans 
to generate practice and policy implications for encouraging university-industry 
engagement in the life sciences, at Edinburgh and beyond. 
The study is expected to conclude at the end of 2013, with a research report and 
policy summary to be produced in mid 2014. 
